Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle Therapy

Posted on by

Phase 1/2a clinical trial will evaluate the safety and efficacy of administering AGLE-102™ to treat severe second-degree burns AGLE-102™ is being developed for the treatment of severe dermatological and immune based disorders WOBURN, Mass., Aug. 16, 2023 /PRNewswire/ — Aegle Therapeutics…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.